JP2020506670A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506670A5 JP2020506670A5 JP2019534112A JP2019534112A JP2020506670A5 JP 2020506670 A5 JP2020506670 A5 JP 2020506670A5 JP 2019534112 A JP2019534112 A JP 2019534112A JP 2019534112 A JP2019534112 A JP 2019534112A JP 2020506670 A5 JP2020506670 A5 JP 2020506670A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- antigen
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022164233A JP2023002635A (ja) | 2016-12-24 | 2022-10-12 | 抗ｐｃｓｋ９抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611210645.3A CN108239150A (zh) | 2016-12-24 | 2016-12-24 | 抗pcsk9抗体及其用途 |
| CN201611210645.3 | 2016-12-24 | ||
| PCT/CN2017/118050 WO2018113781A1 (zh) | 2016-12-24 | 2017-12-22 | 抗pcsk9抗体及其用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022164233A Division JP2023002635A (ja) | 2016-12-24 | 2022-10-12 | 抗ｐｃｓｋ９抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020506670A JP2020506670A (ja) | 2020-03-05 |
| JP2020506670A5 true JP2020506670A5 (https=) | 2020-11-12 |
| JP7167027B2 JP7167027B2 (ja) | 2022-11-08 |
Family
ID=62624551
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534112A Active JP7167027B2 (ja) | 2016-12-24 | 2017-12-22 | 抗ｐｃｓｋ９抗体およびその使用 |
| JP2022164233A Pending JP2023002635A (ja) | 2016-12-24 | 2022-10-12 | 抗ｐｃｓｋ９抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022164233A Pending JP2023002635A (ja) | 2016-12-24 | 2022-10-12 | 抗ｐｃｓｋ９抗体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11485795B2 (https=) |
| EP (1) | EP3560961A4 (https=) |
| JP (2) | JP7167027B2 (https=) |
| KR (1) | KR102331021B1 (https=) |
| CN (2) | CN108239150A (https=) |
| AU (1) | AU2017379048B2 (https=) |
| BR (1) | BR112019012648A2 (https=) |
| CA (1) | CA3047049C (https=) |
| WO (1) | WO2018113781A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108239150A (zh) * | 2016-12-24 | 2018-07-03 | 信达生物制药(苏州)有限公司 | 抗pcsk9抗体及其用途 |
| CN110464842B (zh) * | 2018-05-11 | 2022-10-14 | 信达生物制药(苏州)有限公司 | 包含抗pcsk9抗体的制剂及其用途 |
| CA3155065A1 (en) * | 2019-09-19 | 2021-03-25 | Innovent Biologics (Suzhou) Co., Ltd. | Use of anti-pcsk9 antibody in method for preventing or treating cholesterol-related disease |
| IL292973B2 (en) * | 2019-11-18 | 2026-03-01 | Ad Pharmaceuticals Co Ltd | Anti-PCSK9 antibody and its use |
| CN116983434B (zh) * | 2023-09-28 | 2024-03-15 | 康霖生物科技（杭州）有限公司 | 用于基因治疗的核酸构建体及其用途 |
| WO2026082095A1 (en) * | 2024-10-17 | 2026-04-23 | Innovent Biologics (Suzhou) Co., Ltd. | Compounds for treating metabolic disorders |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| KR100978980B1 (ko) | 2006-02-14 | 2010-08-30 | 엑손모빌 케미칼 패턴츠 인코포레이티드 | 엠씨엠-22계 분자체의 제조 방법 |
| US7572618B2 (en) * | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| EP3124497B1 (en) | 2007-09-14 | 2020-04-15 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Ｐｃｓｋ９拮抗劑類 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| KR102318383B1 (ko) | 2010-07-16 | 2021-10-27 | 아디맵 엘엘씨 | 항체 라이브러리 |
| US8821865B2 (en) | 2010-11-11 | 2014-09-02 | Abbvie Biotechnology Ltd. | High concentration anti-TNFα antibody liquid formulations |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| CN105001336A (zh) * | 2014-04-18 | 2015-10-28 | 上海复旦张江生物医药股份有限公司 | Pcsk9拮抗剂 |
| WO2015200438A1 (en) | 2014-06-24 | 2015-12-30 | Eleven Biotherapeutics, Inc. | High affinity antibodies against pcsk9 |
| CN106084058B (zh) * | 2015-07-15 | 2019-08-27 | 北京天广实生物技术股份有限公司 | 抗人pcsk9单克隆抗体 |
| CN105348390B (zh) * | 2015-10-26 | 2018-08-28 | 北京智仁美博生物科技有限公司 | 抗人pcsk9单克隆抗体 |
| CN105801701B (zh) * | 2016-03-31 | 2019-03-29 | 河北仁博科技有限公司 | 一种pcsk9抗体的重链和轻链可变区及其应用 |
| CN108239150A (zh) | 2016-12-24 | 2018-07-03 | 信达生物制药(苏州)有限公司 | 抗pcsk9抗体及其用途 |
| JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| CN110464842B (zh) | 2018-05-11 | 2022-10-14 | 信达生物制药(苏州)有限公司 | 包含抗pcsk9抗体的制剂及其用途 |
-
2016
- 2016-12-24 CN CN201611210645.3A patent/CN108239150A/zh active Pending
-
2017
- 2017-12-22 WO PCT/CN2017/118050 patent/WO2018113781A1/zh not_active Ceased
- 2017-12-22 BR BR112019012648-1A patent/BR112019012648A2/pt active Search and Examination
- 2017-12-22 CA CA3047049A patent/CA3047049C/en active Active
- 2017-12-22 US US16/473,245 patent/US11485795B2/en active Active
- 2017-12-22 JP JP2019534112A patent/JP7167027B2/ja active Active
- 2017-12-22 EP EP17883464.4A patent/EP3560961A4/en active Pending
- 2017-12-22 KR KR1020197021287A patent/KR102331021B1/ko active Active
- 2017-12-22 AU AU2017379048A patent/AU2017379048B2/en active Active
- 2017-12-22 CN CN201780080278.6A patent/CN110177810B/zh active Active
-
2022
- 2022-10-12 JP JP2022164233A patent/JP2023002635A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506670A5 (https=) | ||
| KR101702194B1 (ko) | 전구단백질 전환효소 섭틸리신 켁신 타입 ９ (ｐｃｓｋ９)에 대한 항원 결합 단백질 | |
| JP2013542194A5 (https=) | ||
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| RU2013155906A (ru) | Антитела анти-angptl3 и их применение | |
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| JP2015514110A5 (https=) | ||
| RU2019104980A (ru) | Анти-icos антитела | |
| RU2016123839A (ru) | Новые модуляторы и способы их применения | |
| IL213050A (en) | Antibody from a person who binds 9pcsk | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| KR20140031938A (ko) | 콜레스테롤 관련 질환을 치료 또는 예방하는 방법 | |
| JP2020511946A5 (https=) | ||
| RU2017104800A (ru) | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) | |
| JP2015503909A5 (https=) | ||
| JP2022533538A5 (https=) | ||
| RU2014127287A (ru) | Антитела, используемые для пассивной вакцинации против гриппа | |
| JP2020522280A5 (https=) | ||
| JP2016520595A5 (https=) | ||
| JP2020522281A5 (https=) | ||
| JP2019512472A5 (https=) | ||
| RU2019125975A (ru) | Связывающие агенты | |
| JP2019528046A5 (https=) | ||
| JP2023503396A5 (https=) |